Pipeline
Keys for hard locks.
Each program starts with a disease target that is hard for other drug types to block. One is in a Phase 1 study.
- 5
- programs
- 1
- in the clinic
- 3
- disease areas
- 1
- partnered program
| Program | Disease | Target | Type | Stage |
|---|---|---|---|---|
| KL-101: Head and neck squamous cell carcinoma | Head and neck squamous cell carcinomaOncology | EGFR (ligand-binding domain III) | De novo designed miniprotein | |
| KL-118: Colorectal cancer | Colorectal cancerOncology | Not disclosed | T-cell engager (bispecific) | |
| KL-204: Ulcerative colitis | Ulcerative colitisImmunology | IL-23 receptor (IL-23R) | De novo designed miniprotein | |
| KL-310: Idiopathic pulmonary fibrosis | Idiopathic pulmonary fibrosisFibrosis | Not disclosed | De novo designed miniprotein | |
| KL-P1: Autoimmune disease | Autoimmune disease · with AldermoorImmunology | Not disclosed | De novo designed miniprotein |
All programs are investigational. None is approved by the FDA or any other agency, and their safety and efficacy have not been established. Stages show where each program is today; dates and plans can change.
Work with us on a target.
We partner with drug companies on targets that are hard for their current tools.